Highlights
Eli Lilly acquired Ajax Therapeutics — Deal value: up to $2.3B
Eli Lilly is a U.S. drugmaker expanding its oncology pipeline. Ajax Therapeutics is a privately held cancer drug developer with an early-stage oral treatment for myelofibrosis. The deal supports Lilly’s search for next-generation cancer treatments. It also builds on Lilly’s blood cancer capabilities and could expand future commercial products beyond obesity. Agency lens: This is a pipeline-exp...
Get Unlimited NextBigWin Access
Subscribe to become a NextBigWin Pro member and get access to all our exclusive content. Turn access and intelligence into your next big client win.